The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan

Biochemical Pharmacology

Volumn 76, Issue 6, 2008, Pages 763-772

  Alonen, Anna ^a   Finel, Moshe ^a   Kostiainen, Risto ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Candesartan; Losartan; Substrate specificity; Tetrazole; UDP glucuronosyltransferases; Zolarsartan (GR117289)

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN; GLUCURONOSYLTRANSFERASE 1A3; LOSARTAN; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; ZOLARSARTAN; ZOLASARTAN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; COW; DRUG CONJUGATION; DRUG GLUCURONIDATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME KINETICS; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; LIVER MICROSOME; MOOSE; NONHUMAN; PRIORITY JOURNAL; RAT; SWINE;

ANIMALS; BENZIMIDAZOLES; CATTLE; DEER; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; LOSARTAN; MALE; MICROSOMES, LIVER; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; SUBSTRATE SPECIFICITY; SWINE; TETRAZOLES;

EID: 50549104173     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.07.006     Document Type: Article

References (40)

1. Habashi J.P., Judge D.P., Holm T.M., Cohn R.D., Loeys B.L., Cooper T.K., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312 (2006) 117-121
2. Matt P., Habashi J., Carrel T., Cameron D.E., Van Eyk J.E., and Dietz H.C. Recent advances in understanding Marfan syndrome: should we now treat surgical patients with losartan?. J Thorac Cardiovasc Surg 135 (2008) 389-394
3. Travis J. Medicine. Old drug, new hope for Marfan syndrome. Science 312 (2006) 36-37
4. Lacro R.V., Dietz H.C., Wruck L.M., Bradley T.J., Colan S.D., Devereux R.B., et al. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J 154 (2007) 624-631
5. Robertson M.J., Barnes J.C., Drew G.M., Clark K.L., Marshall F.H., Michel A., et al. Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist. Br J Pharmacol 107 (1992) 1173-1180
6. Hilditch A., Hunt A.A., Gardner C.J., Twissell D.J., Polley J., Travers A., et al. Cardiovascular effects of GR117289, a novel angiotensin AT1 receptor antagonist. Br J Pharmacol 111 (1994) 137-144
7. Stearns R.A., Miller R.R., Doss G.A., Chakravarty P.K., Rosegay A., Gatto G.J., et al. The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices. Drug Metab Dispos 20 (1992) 281-287
8. Fenton C., and Scott L.J. Candesartan cilexetil: a review of its use in the management of chronic heart failure. Drugs 65 (2005) 537-558
9. Kondo T., Yoshida K., Yoshimura Y., Motohashi M., and Tanayama S. Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs. Arzneimittelforschung 46 (1996) 594-600
10. Kondo T., Yoshida K., Yoshimura Y., Motohashi M., and Tanayama S. Characterization of conjugated metabolites of a new angiotensin II receptor antagonist, candesartan cilexetil, in rats by liquid chromatography/electrospray tandem mass spectrometry following chemical derivatization. J Mass Spectrom 31 (1996) 873-878
11. Bowers G.D., Eddershaw P.J., Hughes S.Y., Manchee G.R., and Oxford J. Characterization of glucuronic acid conjugates of a novel angiotensin receptor antagonist. Rapid Commun Mass Spectrom 8 (1994) 217-221
12. King C.D., Rios G.R., Green M.D., and Tephly T.R. UDP-glucuronosyltransferases. Curr Drug Metab 1 (2000) 143-161
13. Ritter J.K. Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chem Biol Interact 129 (2000) 171-193
14. Tukey R.H., and Strassburg C.P. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40 (2000) 581-616
15. Ouzzine M., Barre L., Netter P., Magdalou J., and Fournel-Gigleux S. The human UDP-glucuronosyltransferases: structural aspects and drug glucuronidation. Drug Metab Rev 35 (2003) 287-303
16. Kiang T.K., Ensom M.H., and Chang T.K. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106 (2005) 97-132
17. Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenom J 3 (2003) 136-158
18. Mackenzie P.I., Walter Bock K., Burchell B., Guillemette C., Ikushiro S., Iyanagi T., et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genom 15 (2005) 677-685
19. Radominska-Pandya A., Czernik P.J., Little J.M., Battaglia E., and Mackenzie P.I. Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 31 (1999) 817-899
20. Stearns R.A., Doss G.A., Miller R.R., and Chiu S.H. Synthesis and identification of a novel tetrazole metabolite of the angiotensin II receptor antagonist DuP 753. Drug Metab Dispos 19 (1991) 1160-1162
21. Alonen A., Jansson J., Kallonen S., Kiriazis A., Aitio O., Finel M., et al. Enzyme-assisted synthesis and structure characterization of glucuronic acid conjugates of losartan, candesartan, and zolarsartan. Bioorg Chem 36 (2008) 148-155
22. Huskey S.W., Miller R.R., and Chiu S.H.L. N-Glucuronidation reaction. I. Tetrazole N-glucuronidation of selected angiotensin II receptor antagonists in hepatic microsomes from rats, dogs, monkeys, and humans. Drug Metab Dispos 21 (1993) 792-799
23. Krieter P.A., Colletti A.E., Miller R.R., and Stearns R.A. Absorption and glucuronidation of the angiotensin II receptor antagonist losartan by the rat intestine. J Pharmacol Exp Ther 273 (1995) 816-822
24. Kurkela M., Patana A.S., Mackenzie P.I., Court M.H., Tate C.G., Hirvonen J., et al. Interactions with other human UDP-glucuronosyltransferases attenuate the consequences of the Y485D mutation on the activity and substrate affinity of UGT1A6. Pharmacogenet Genom 17 (2007) 115-126
25. Luukkanen L., Elovaara E., Lautala P., Taskinen J., and Vainio H. Characterization of 1-hydroxypyrene as a novel marker substrate of 3-methylcholanthrene-inducible phenol UDP-glucuronosyltransferase(s). Pharmacol Toxicol 80 (1997) 152-158
26. Stevens J.C., Fayer J.L., and Cassidy K.C. Characterization of 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]methyl]quinoline N-glucuronidation by in vitro and in vivo approaches. Drug Metab Dispos 29 (2001) 289-295
27. Green M.D., King C.D., Mojarrabi B., Mackenzie P.I., and Tephly T.R. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos 26 (1998) 507-512
28. Green M.D., and Tephly T.R. Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins. Drug Metab Dispos 26 (1998) 860-867
29. Kaji H., and Kume T. Characterization of afloqualone N-glucuronidation: species differences and identification of human UDP-glucuronosyltransferase isoform(s). Drug Metab Dispos 33 (2005) 60-67
30. Vashishtha S.C., Hawes E.M., McKay G., and McCann D.J. Quaternary ammonium-linked glucuronidation of 1-substituted imidazoles: studies of human UDP-glucuronosyltransferases involved and substrate specificities. Drug Metab Dispos 29 (2001) 1290-1295
31. Nakajima M., Tanaka E., Kobayashi T., Ohashi N., Kume T., and Yokoi T. Imipramine N-glucuronidation in human liver microsomes: biphasic kinetics and characterization of UDP-glucuronosyltransferase isoforms. Drug Metab Dispos 30 (2002) 636-642
32. Wiener D., Doerge D.R., Fang J.L., Upadhyaya P., and Lazarus P. Characterization of N-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol(NNAL) in human liver: importance of UDP-glucuronosyltransferase 1A4. Drug Metab Dispos 32 (2004) 72-79
33. Herr R.J. 5-Substituted-1H-tetrazoles as carboxylic acid isosteres: medicinal chemistry and synthetic methods. Bioorg Med Chem 10 (2002) 3379-3393
34. Myznikov L.V., Hrabalek A., and Koldobskii G.I. Drugs in the tetrazole series (review). Chem Heterocycl Compd 43 (2007) 1-9
35. Finel M., Li X., Gardner-Stephen D., Bratton S., Mackenzie P.I., and Radominska-Pandya A. Human UDP-glucuronosyltransferase 1A5: identification, expression, and activity. J Pharmacol Exp Ther 315 (2005) 1143-1149
36. Alonen A., Aitio O., Hakala K., Luukkanen L., Finel M., and Kostiainen R. Biosynthesis of dobutamine monoglucuronides and glucuronidation of dobutamine by recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 33 (2005) 657-663
37. Stachulski A.V., Harding J.R., Lindon J.C., Maggs J.L., Park B.K., and Wilson I.D. Acyl glucuronides: biological activity, chemical reactivity, and chemical synthesis. J Med Chem 49 (2006) 6931-6945
38. Bailey M.J., and Dickinson R.G. Acyl glucuronide reactivity in perspective: biological consequences. Chem Biol Interact 145 (2003) 117-137
39. Sallustio B.C., Sabordo L., Evans A.M., and Nation R.L. Hepatic disposition of electrophilic acyl glucuronide conjugates. Curr Drug Metab 1 (2000) 163-180
40. Shipkova M., Armstrong V.W., Oellerich M., and Wieland E. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 25 (2003) 1-16